Thailand · Delayed Price · Currency is THB DOD Biotech PCL Statistics
Total Valuation
DOD Biotech PCL has a market cap or net worth of THB 445.91 million. The enterprise value is 399.69 million.
| Market Cap | 445.91M |
| Enterprise Value | 399.69M |
Important Dates
The next estimated earnings date is Tuesday, November 17, 2026.
| Earnings Date | Nov 17, 2026 |
| Ex-Dividend Date | Mar 13, 2026 |
Share Statistics
DOD Biotech PCL has 450.41 million shares outstanding. The number of shares has increased by 0.52% in one year.
| Current Share Class | 450.41M |
| Shares Outstanding | 450.41M |
| Shares Change (YoY) | +0.52% |
| Shares Change (QoQ) | n/a |
| Owned by Insiders (%) | 12.77% |
| Owned by Institutions (%) | 19.52% |
| Float | 348.79M |
Valuation Ratios
The trailing PE ratio is 125.19.
| PE Ratio | 125.19 |
| Forward PE | n/a |
| PS Ratio | 0.82 |
| PB Ratio | 0.49 |
| P/TBV Ratio | 0.50 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | 213.99 |
| EV / Sales | 0.74 |
| EV / EBITDA | 9.30 |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 2.93, with a Debt / Equity ratio of 0.07.
| Current Ratio | 2.93 |
| Quick Ratio | 1.44 |
| Debt / Equity | 0.07 |
| Debt / EBITDA | 1.57 |
| Debt / FCF | -0.65 |
| Interest Coverage | -0.16 |
Financial Efficiency
Return on equity (ROE) is 0.52% and return on invested capital (ROIC) is -0.06%.
| Return on Equity (ROE) | 0.52% |
| Return on Assets (ROA) | -0.03% |
| Return on Invested Capital (ROIC) | -0.06% |
| Return on Capital Employed (ROCE) | -0.06% |
| Weighted Average Cost of Capital (WACC) | 8.07% |
| Revenue Per Employee | n/a |
| Profits Per Employee | n/a |
| Employee Count | n/a |
| Asset Turnover | 0.49 |
| Inventory Turnover | 3.38 |
Taxes
| Income Tax | -9.66M |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -42.69% in the last 52 weeks. The beta is 0.81, so DOD Biotech PCL's price volatility has been lower than the market average.
| Beta (5Y) | 0.81 |
| 52-Week Price Change | -42.69% |
| 50-Day Moving Average | 1.14 |
| 200-Day Moving Average | 1.54 |
| Relative Strength Index (RSI) | 35.49 |
| Average Volume (20 Days) | 396,843 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, DOD Biotech PCL had revenue of THB 543.07 million and earned 1.87 million in profits. Earnings per share was 0.00.
| Revenue | 543.07M |
| Gross Profit | 177.00M |
| Operating Income | -550,198 |
| Pretax Income | -4.86M |
| Net Income | 1.87M |
| EBITDA | 42.13M |
| EBIT | -550,198 |
| Earnings Per Share (EPS) | 0.00 |
Balance Sheet
The company has 110.35 million in cash and 67.65 million in debt, with a net cash position of 42.71 million or 0.09 per share.
| Cash & Cash Equivalents | 110.35M |
| Total Debt | 67.65M |
| Net Cash | 42.71M |
| Net Cash Per Share | 0.09 |
| Equity (Book Value) | 914.39M |
| Book Value Per Share | 2.04 |
| Working Capital | 255.03M |
Cash Flow
In the last 12 months, operating cash flow was -22.95 million and capital expenditures -81.69 million, giving a free cash flow of -104.64 million.
| Operating Cash Flow | -22.95M |
| Capital Expenditures | -81.69M |
| Depreciation & Amortization | 42.68M |
| Net Borrowing | 10.55M |
| Free Cash Flow | -104.64M |
| FCF Per Share | -0.23 |
Margins
Gross margin is 32.59%, with operating and profit margins of -0.10% and 0.34%.
| Gross Margin | 32.59% |
| Operating Margin | -0.10% |
| Pretax Margin | -0.89% |
| Profit Margin | 0.34% |
| EBITDA Margin | 7.76% |
| EBIT Margin | -0.10% |
| FCF Margin | n/a |
Dividends & Yields
This stock pays an annual dividend of 0.05, which amounts to a dividend yield of 5.10%.
| Dividend Per Share | 0.05 |
| Dividend Yield | 5.10% |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | 1,205.70% |
| Buyback Yield | -0.52% |
| Shareholder Yield | 4.59% |
| Earnings Yield | 0.42% |
| FCF Yield | -23.47% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | |
| Lynch Upside | |
| Graham Number | |
| Graham Upside |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
DOD Biotech PCL has an Altman Z-Score of 3.07 and a Piotroski F-Score of 1.
| Altman Z-Score | 3.07 |
| Piotroski F-Score | 1 |